YOLFTbeta
Sellas Life Sciences Group Inc

Sellas Life Sciences Group Inc

SLS · NASDAQ · Healthcare / Biotechnology

7.86USD-0.17 (-2.12%)

Price History

Full chart

Market Stats

Previous Close8.03
Open8.69
Day Range7.54 – 9.00
52-Week Range1.39 – 15.88
Volume11.12M
Market Cap2.05B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.21
Dividend Yield0.00%
Beta2.57
50-Day Avg12.31
200-Day Avg8.51

About

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Angelos M. Stergiou M.D., ScD h.c.
  • Employees13
  • Headquarters7 Times Square, New York, NY, United States, 10036, USA
  • Websitehttps://sellaslifesciences.com

Leadership

  • Dr. Angelos M. Stergiou M.D., ScD h.c.Founder, President, CEO & Director · b. 1976
  • Mr. John Thomas Burns CPASenior VP & CFO · b. 1985
  • Dr. Dragan Cicic M.D., MBASenior VP & Chief Development Officer · b. 1963
  • Ms. Stacy E. YeungVP, General Counsel & Corporate Secretary
  • Mr. Andrew ElnatanSenior VP of Regulatory Affairs, CMC & Quality

Financials

Income Statement

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----02.04M2.49M9.32M000001.90K7.60M1.00M000
Growth (%)-------+22.03%+274.71%-100.00%-----+399900.00%-86.84%-100.00%--
Cost of Revenue-11.41M---163.00K49.00K520.00K1.40M355.00K3.00K00-377.00K200.00K100.00K0--
Gross Profit--11.41M----20.79M2.04M1.97M7.92M-355.00K-3.00K00-1.90K7.40M900.00K0--
Gross Margin------100.00%79.09%84.94%-----100.00%97.37%90.00%---
Operating Expense-0---023.24M35.81M44.52M33.87M15.98M15.71M31.59M-16.98M32.69M42.85M37.87M--
Operating Income-2.40M-11.41M-14.55M-17.52M-16.63M-20.79M-21.20M-33.84M-36.61M-34.22M-15.99M-15.71M-31.59M-20.04M-16.98M-25.29M-41.95M-37.87M-31.51M-28.27M
Operating Margin-------1040.19%-1360.68%-392.81%------893789.47%-332.82%-4195.00%---
EBITDA-2.40M-10.93M-14.24M-18.22M-11.82M-11.32M-21.15M7.63M-34.61M-37.48M-15.98M-22.78M-6.74M668.00K26.52M-18.32M-31.49M529.00K632.00K-26.86M
EBITDA Margin-------1037.78%306.71%-371.36%-----1396015.79%-241.07%-3149.30%---
Net Income-2.40M-10.99M-14.37M-18.39M-11.99M-11.48M-34.97M-76.68M-36.61M-63.90M-23.55M-23.75M-27.67M-19.29M-16.76M-20.70M-41.30M-37.34M-30.88M-26.86M
Net Income Margin-------1715.85%-3083.15%-392.81%------881947.37%-272.36%-4130.10%---
R&D1.30M6.75M7.05M8.89M7.87M11.54M14.61M21.08M28.35M23.61M19.86M6.07M18.32M10.12M9.28M21.37M30.27M24.01M19.10M16.02M
R&D as % of Total Revenue------717.08%847.45%304.26%-----488526.32%281.24%3026.80%---
Interest Expense0005.00K5.00K033.00K807.00K1.11M760.00K3.51M462.00K266.00K118.00K390.00K4.36M649.00K---
Interest Expense % of Total Revenue------1.62%32.45%11.91%-----20526.32%57.34%64.90%---

Balance Sheet

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.00K12.15M10.36M6.25M7.48M30.97M54.99M87.98M80.49M82.14M65.81M33.53M16.91M16.61M46.05M26.43M20.94M6.22M19.43M78.34M
Total Liabilities-1.32M1.39M5.51M5.05M20.86M27.23M82.09M43.43M68.63M37.15M31.46M11.67M10.52M18.09M6.08M16.09M14.20M9.97M7.47M
Total Equity2.00K10.82M8.97M741.00K2.43M10.11M27.76M5.89M37.06M13.51M28.66M2.07M5.25M6.09M27.96M20.35M4.85M-7.98M9.46M70.87M
Cash2.00K1.76M9.86M5.68M6.89M11.43M32.81M47.79M23.65M29.73M18.08M2.32M5.34M7.28M35.30M21.45M17.13M2.53M13.89M71.89M
Total Debt--21.00K88.00K71.00K567.00K57.00K9.92M8.40M4.74M22.06M10.99M-217.00K991.00K808.00K945.00K906.00K1.00M1.00M
Net Debt-2.00K-1.76M-9.84M-5.60M-6.82M-10.87M-32.75M-37.86M-15.25M-24.99M-1.69M8.67M-5.34M-7.06M-34.31M-20.65M-16.18M-1.62M-12.88M-70.89M

Cash Flow

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.11M-6.05M-9.43M-11.77M-10.26M-14.67M-20.96M-28.91M-42.87M-48.16M-44.91M-10.99M-30.42M-17.64M-10.42M-26.02M-23.81M-31.41M-35.40M-28.39M
Investing Cash Flow--10.03M9.60M-83.00K-106.00K14.00K-87.00K-12.04M-5.53M10.39M-1.06M1.81M--4.50M-4.50M-4.50M-4.50M-5.50M--
Financing Cash Flow2.11M17.83M7.92M7.68M11.57M19.20M42.42M55.92M24.26M43.84M34.32M5.53M23.12M19.57M38.44M12.07M24.08M22.32M46.76M86.30M
Capital Expenditure0229.00K166.00K83.00K106.00K53.00K739.00K15.85M5.53M153.00K6.00K000004.50M5.50M00
Free Cash Flow-2.11M-6.28M-9.60M-11.85M-10.36M-14.72M-20.96M-44.76M-48.40M-48.31M-44.92M-10.99M-30.42M-17.64M-10.42M-26.02M-28.31M-36.91M-35.40M-28.39M
Dividends Paid----464.00K0000487.00K487.00K675.00K487.00K0------
FCF to OCF100.00%103.79%101.76%100.71%101.03%100.36%100.00%154.82%112.90%100.32%100.01%100.00%100.00%100.00%100.00%100.00%118.90%117.51%100.00%100.00%
Dividend Paid to FCF-----4.48%0.00%0.00%0.00%0.00%-1.01%-1.08%-6.14%-1.60%0.00%------

Earnings

Report DateMay 20, 2008Aug 14, 2008Nov 14, 2008Mar 18, 2009May 15, 2009Aug 14, 2009Nov 16, 2009Mar 31, 2010May 17, 2010Aug 11, 2010Nov 15, 2010May 15, 2011Aug 15, 2011Nov 14, 2011Mar 28, 2012May 14, 2012Aug 14, 2012Nov 13, 2012Mar 12, 2013May 9, 2013Aug 8, 2013Nov 6, 2013Mar 17, 2014May 6, 2014Aug 11, 2014Nov 3, 2014Mar 5, 2015May 7, 2015Aug 6, 2015Nov 9, 2015Mar 10, 2016May 10, 2016Aug 9, 2016Nov 9, 2016Mar 15, 2017May 10, 2017Aug 14, 2017Nov 9, 2017Mar 15, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Mar 22, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Mar 13, 2020May 14, 2020Aug 13, 2020Nov 13, 2020Mar 23, 2021May 13, 2021Aug 12, 2021Nov 12, 2021Mar 31, 2022May 12, 2022Aug 11, 2022Nov 14, 2022Mar 16, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 28, 2024May 14, 2024Aug 13, 2024Nov 13, 2024Mar 26, 2025May 13, 2025Aug 12, 2025Nov 12, 2025Mar 19, 2026May 19, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate-9600.00-6600.00-9600.002400.00-8700.00-9000.00--7500.00-8100.00-7200.00-7050.00--2100.00-4800.00-4500.00-3000.00-4800.00-2550.00-3042.86-2228.57-3112.50-3300.00-2766.67-2062.50-2700.00-3412.50-3150.00-2600.00-2760.00-2057.14-1600.00-1920.00-1875.00-1350.00-780.00-330.00-270.00-225.00-1.06-46.50-51.50-20.25-11.75-10.25-9.00-1.00-0.72-0.68-0.64-0.34-0.28-0.36-0.39-0.34-0.41-0.42-0.37-0.39-0.32-0.29-0.350.020.09-0.16-0.17-0.13-0.11-0.11-0.08-0.08-0.06-0.07-0.04-0.05
EPS Actual-11700.00-10200.00-7500.00-8700.00-9000.00-11100.00-5846.95-11400.00-7200.00-3600.00-6900.00-5672.40-1200.00-3900.001200.00-15600.00-210.00-2700.00-1200.00-3300.00-3300.00-3300.00-13800.00-600.00-5100.00-1500.00-1800.00-2400.00-3000.00-3300.00-1500.00-2700.001200.00-900.00-735.00-675.00-330.00-30.00-49.50-83.50-63.00-26.50-8.50-9.71-6.19-0.96-1.54-0.63-0.63-0.53-0.28-0.16-0.30-0.45-0.42-0.42-0.42-0.34-0.43-0.47-0.31-0.33-0.25-0.21-0.13-0.10-0.08-0.07-0.07-0.06-0.05-0.05-0.05-
Surprise-21.88%-54.55%21.88%-462.50%-3.45%-23.33%--52.00%11.11%50.00%2.13%-42.86%18.75%126.67%-420.00%95.63%-5.88%60.56%-48.08%-6.02%0.00%-398.79%70.91%-88.89%56.04%42.86%7.69%-8.70%-60.42%6.25%-40.63%164.00%33.33%5.77%-104.55%-22.22%86.67%-4569.81%-79.57%-22.33%-30.86%27.66%5.27%31.22%4.00%-113.89%7.35%1.56%-55.88%0.00%55.56%23.08%-32.35%-2.44%0.00%-13.51%12.82%-34.38%-62.07%11.43%-1750.00%-377.78%-31.25%23.53%23.08%25.02%36.36%12.50%25.00%16.67%30.43%-25.00%-
Timing-------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap2.05B
Enterprise Value1.96B
Trailing P/E0.00
Forward P/E0.00
Price / Sales26.90
Price / Book15.24
EPS-0.21
Book Value0.682
Revenue (TTM)0
Gross Profit (TTM)900.00K
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-39.63%
Return on Assets-23.30%
Shares Outstanding201.95M
Shares Float201.15M
Beta2.57
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 32.50
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
37.06%
Insiders
0.92%
Retail / Other
62.02%

Top Institutional Holders

  • BlackRock Inc
    15.07M7.46%
  • State Street Corp
    13.00M6.44%
  • Vanguard Capital Management, LLC
    8.23M4.07%
  • Geode Capital Management, LLC
    4.88M2.42%
  • Anson Funds Management LP
    4.50M2.23%
  • JONES FINANCIAL COMPANIES LLLP
    2.30M1.14%
  • Vanguard Portfolio Management, LLC
    2.16M1.07%
  • Susquehanna International Group, LLP
    2.05M1.02%
  • Northern Trust Corp
    1.62M0.80%
  • Dagco Inc
    1.34M0.66%
  • Vanguard Fiduciary Trust Co
    1.34M0.66%
  • UBS Group AG
    1.25M0.62%
  • Morgan Stanley - Brokerage Accounts
    1.24M0.61%
  • BNP Paribas Arbitrage, SA
    1.07M0.53%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    6.45M3.19%
  • State Street® SPDR® S&P® Biotech ETF
    5.70M2.82%
  • iShares Russell 2000 ETF
    5.21M2.58%
  • Fidelity Small Cap Index
    2.06M1.02%
  • iShares Russell 2000 Growth ETF
    1.88M0.93%
  • Vanguard Russell 2000 ETF
    1.17M0.58%

Stock Splits

  • Nov 8, 20191:50
  • Jan 2, 20181:30
  • Nov 14, 20161:20